VTYX
Ventyx Biosciences Inc
NASDAQ: VTYX · HEALTHCARE · BIOTECHNOLOGY
$14.00
+0.00% today
Updated 2026-03-04
Market cap
$1.00B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.49
Dividend yield
—
52W range
$1 – $15
Volume
4.1M
Ventyx Biosciences Inc (VTYX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | — | — | $30000.00 | $470000.00 | $941000.00 | $1.35M |
| Gross profit | — | — | $-30000.00 | $-470000.00 | $-941000.00 | $-1.35M |
| Gross margin | — | — | — | — | — | — |
| R&D | $3.55M | $6.37M | $58.48M | $87.74M | $175.77M | $117.00M |
| SG&A | $628000.00 | $684000.00 | $8.67M | $25.40M | $32.23M | $31.45M |
| Operating income | $-4.18M | $-7.05M | $-67.15M | $-113.14M | $-207.99M | $-148.45M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-1000.00 | $-7.05M | $-83.62M | $-112.67M | $-207.05M | $-147.10M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-4.18M | $-14.10M | $-83.65M | $-113.14M | $-207.99M | $-148.45M |
| Interest expense | $146000.00 | $358000.00 | $99000.00 | $4.71M | — | — |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-4.47M | $-28.17M | $-83.75M | $-108.43M | $-192.96M | $-135.12M |
| Net income growth (YoY) | — | -529.9% | -197.2% | -29.5% | -78.0% | +30.0% |
| Profit margin | — | — | — | — | — | — |